Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
143.31
300.55
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Cash & Cash Equivalents
Alnylam Pharmaceuticals Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Cash & Cash Equivalents
$1.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
30%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$7.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$5B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$6.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$2B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
8%
|
CAGR 10-Years
12%
|
|
Alnylam Pharmaceuticals Inc
Glance View
Alnylam Pharmaceuticals Inc. is at the forefront of transforming the landscape of genetic medicine through its pioneering work in RNA interference (RNAi) technology. Founded in 2002, the company embarked on a bold mission to develop innovative therapies for rare and challenging diseases caused by genetic mutations. By leveraging the power of RNAi, Alnylam enables the silencing of specific disease-causing genes, offering a potential cure rather than just symptomatic relief. Their flagship products, like Onpattro and GIVLAARI, have already gained approval for treating debilitating conditions such as hereditary transthyretin-mediated amyloidosis and acute hepatic porphyria, making waves in the biotechnology sector and establishing the company as a leader in genetic medicines. Investors have taken note of Alnylam's unique position in a rapidly evolving market, propelled by its strong pipeline of therapies aimed at multiple diseases. With a robust clinical trial framework and strategic partnerships with major pharmaceutical players, Alnylam not only raises its profile but also enhances its growth potential. The company is on a path to deliver multiple additional product candidates and expand its therapeutic reach into areas like cardiometabolic and neurodegenerative diseases. For those looking to invest in a company that combines scientific innovation with robust market potential, Alnylam Pharmaceuticals represents a compelling narrative filled with promise and transformative possibilities in the realm of healthcare.
See Also
What is Alnylam Pharmaceuticals Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.1B
USD
Based on the financial report for Sep 30, 2024, Alnylam Pharmaceuticals Inc's Cash & Cash Equivalents amounts to 1.1B USD.
What is Alnylam Pharmaceuticals Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
30%
Over the last year, the Cash & Cash Equivalents growth was 6%.
You don't have any saved screeners yet
